Table 1.

The in vitro cytotoxicity of compounds against various cell lines. A549—human non-small-cell lung cancer; MCF-7—human mammary cancer; HepG2—human hepatocellular carcinoma; MDCK—Madin–Darby canine kidney; H9c2—murine heart myoblast; He—hederagenin; DDP—cisplatin.

Half Maximal Inhibitory Concentration (IC50) Values (μM)
Compound	A549	MCF-7	HepG2	MDCK	H9c2
1	17.62 ± 0.37	16.05 ± 0.01	18.79 ± 0.04	18.06 ± 0.25	14.73 ± 0.51
2	20.55 ± 0.29	15.78 ± 0.22	27.23 ± 1.82	26.71 ± 1.64	25.09 ± 0.43
3	15.03 ± 0.35	16.83 ± 9.25	18.93 ± 0.35	18.42 ± 3.76	>30
4	17.07 ± 1.06	17.31 ± 0.48	25.53 ± 1.40	26.12 ± 1.02	20.42 ± 2.24
5	24.37 ± 0.37	>30	24.94 ± 0.06	23.53 ± 0.67	28.46 ± 0.29
6	25.52 ± 0.26	>30	>30	24.08 ± 0.76	>30
7	>30	>30	>30	>30	>30
8	23.92 ± 0.31	25.35 ± 0.09	17.41 ± 0.75	20.13 ± 0.30	21.66 ± 0.86
9	3.45 ± 0.59	8.73 ± 1.49	8.71 ± 0.38	14.11 ± 0.04	16.69 ± 0.12
10	20.93 ± 0.68	27.24 ± 2.09	28.17 ± 0.21	25.42 ± 0.28	19.60 ± 3.29
11	14.12 ± 0.01	27.30 ± 0.57	14.84 ± 0.03	18.64 ± 0.18	14.72 ± 0.16
12	10.05 ± 2.47	17.28 ± 0.58	14.42 ± 0.03	18.64 ± 0.71	13.16 ± 0.20
13	8.15 ± 0.17	18.03 ± 0.18	13.24 ± 0.29	23.22 ± 0.01	10.51 ± 0.61
14	17.60 ± 2.33	31.23 ± 0.15	7.05 ± 0.17	18.10 ± 0.12	15.90 ± 0.22
15	17.98 ± 0.04	19.77 ± 1.27	6.71 ± 0.20	17.12 ± 1.01	17.56 ± 1.85
16	24.78 ± 0.66	28.49 ± 0.28	6.99 ± 0.63	20.12 ± 0.06	14.99 ± 0.12
17	19.57 ± 0.22	22.88 ± 0.66	8.15 ± 0.22	20.93 ± 3.03	22.31 ± 0.30
18	16.17 ± 0.15	28.29 ± 0.41	11.91 ± 0.99	16.55 ± 0.22	>30
19	12.23 ± 0.4	27.57 ± 0.52	9.06 ± 0.32	16.43 ± 0.04	16.50 ± 0.22
20	>30	>30	>30	>30	>30
21	9.29 ± 0.99	24.98 ± 0.18	7.99 ± 0.12	14.85 ± 0.06	16.68 ± 0.10
22	10.40 ± 0.43	20.53 ± 3.63	7.15 ± 0.43	16.34 ± 1.57	16.26 ± 0.07
23	18.67 ± 0.32	21.26 ± 1.28	7.17 ± 1.09	19.49 ± 2.47	23.35 ± 0.55
24	21.97 ± 0.87	17.95 ± 2.80	6.89 ± 0.21	19.27 ± 1.47	27.87 ± 0.62
25	>30	15.63 ± 1.41	6.42 ± 0.24	>30	>30
26	>30	18.30 ± 1.16	7.15 ± 0.85	>30	>30
He	>50	>50	>50	>50	>50
DDP	3.85 ± 0.63	5.17 ± 0.28	3.42 ± 0.68	9.97 ± 1.12	5.31 ± 0.26